Alectinib is a novel FDA-approved, targeted therapy used to treat ALK(anaplastic lymphoma kinase)-positive advanced non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer and is the leading cause of cancer-related deaths worldwide. ALK-positive NSCLC is a rare and aggressive form of lung cancer caused by a genetic abnormality in the ALK gene. Alectinib works by specifically targeting the cancer cells with the abnormal ALK gene, potentially providing a more personalized approach to treating NSCLC. Dosage of alectinib administration Alectinib is administered as a once-daily 150mg dose either orally or intravenously. It is combined with other drugs such as chemotherapy, immunotherapy, and other targeted therapies following the progression or recurrence of the disease. Alectinib has displayed superior efficacy in comparison to other existing ALK inhibitors such as crizotinib, with higher response and progression-free survival rates. Side effects due to alectinib A